降脂护肝胶囊治疗脂肪肝临床观察  

Clinical investigation of Jiangzhi hugan capsules treating patients with fatty liver

作　　者：邱一华 谭俊铭 沈洁 孔飞飞 郭良君 

机构地区：[1]解放军第九八医院心内科,浙江省湖州市313000 [2]解放军第九八医院骨六科,浙江省湖州市313000 [3]解放军第九八医院药械科,浙江省湖州市313000

出　　处：《中国医药》2013年第10期1422-1424,共3页China Medicine

摘　　要：目的观察降脂护肝胶囊治疗脂肪肝的临床疗效。方法将190例脂肪肝患者完全随机分为降脂护肝胶囊组和血脂康胶囊组，各95例。降脂护肝胶囊组采用降脂护肝胶囊治疗，血脂康胶囊组采用血脂康胶囊治疗。治疗6个月后，对治疗前后的症状与体征、肝功能、血脂和B型超声等指标进行评价。结果降脂护肝胶囊组总有效率为96．8％（92／95），明显高于血脂康胶囊组总有效率[76．8％（72／95）]，差异有统计学意义（P〈0．05）。治疗后降脂护肝胶囊组和血脂康胶囊组患者AST、ALT、γ-谷氨酰转肽酶（γ-GT）、TC及TG、LDL—C水平均明显低于治疗前[降脂护肝胶囊组：（32±13）U／L比（67±30）U／L，（43±12）U／L比（89±31）U／L，（47±19）U／L比（96±42）U／L，（5．1±0．4）mmo]／L比（7．2±1．6）mmol／L，（1．5±0．7）mmol／L比（3．4±2．2）mmo]／L，（3．1±2．1）mmol／L比（3．8±1．6）mmol／L；血脂康胶囊组：（44±16）U／L比（69±30）U／L，（55±15）U／L比（87±31）U／L，（60±22）U／L比（99±46）U／L，（6．3±0．7）mmol／L比（7．5±1．4）mmol／L，（2．9±0．8）mmoL／L比（3．4±2．5）mmo]／L，（3．3±1．9）mmoL／L比（3．6±2．1）mmoL／L]，HDL—C水平明显高于治疗前[降脂护肝胶囊组：（1．5±0．6）mmol／L比（1．0±0．7）mmol／L；血脂康胶囊组：（1．2±0．7）mmol／L比（0．9±0．9）mmol／L]，差异均有统计学意义（P〈0．01或P〈0．05）；降脂护肝胶囊组治疗后AST、γ-GT、TC及TG水平均明显低于血脂康胶囊组，HDL—C水平明显高于血脂康胶囊组，差异均有统计学意义（P〈0．05）。结论降脂护肝胶囊具有良好的保肝降脂作用。Objective To investigate the effect of Jiangzhi gugan capsules on fatty liver. Methods All 190 patients with fatty liver were randomly divided into treatment group and control group （95 cases in each group）. The treatment group were treated with Jiangzhi hugan capsules, and control group were treated with xuezhikang capsules. Six months after treatment, the symptoms and signs before and after treatment, liver function, blood lipids and B ultrasonic were evaluated. Results The total effective rate was 96.8% （92/95） in treatment group, which was higher than that in control group [ 76.8 % （72/95） ], and there was significant difference （P 〈 0.05 ）. After treatment, the levels of ALT, AST, γ-GT, TC, TG and LDL-C were lower than those before treatment in two groups [ treatment group ： （ 32 ± 13 ） U/L vs （67 ± 30） U/L, （43 ± 12 ） U/L vs （ 89 ± 31 ） U/L, （47 ± 19 ） U/L vs （ 96 ± 42） U/L, （ 5.1 ± 0.4） mmol/L vs （ 7.2 ± 1.6 ） mmol/L, （ 1.5 ± 0.7 ） mmol/L vs （ 3.4 ± 2.2 ） mmo]/L, （ 3. 1 ± 2.1）mmol/L vs （3.8 ± 1.6）retool/L; control group： （44 ± 16）U/L vs （69 ±30）U/L, （55 ± 15）U/L vs （87 ± 31 ） U/L, （ 60 ± 22 ） U/L vs （ 99 ± 46 ） U/L, （ 6.3 ± 0.7 ） mmol/L vs （ 7.5 ± 1.4 ） retool/L, （ 2.9 ± 0.8 ） mmol/L vs （3.4 ± 2.5 ） mmol/L, （ 3.3 ± 1.9 ） mmol/L vs （ 3.6 ± 2.1 ） mmol/L], and the level of HDL-C were higher than those before treatment in two groups [ treatment group ： （ 1.5 ± 0.6 ） mmol/L vs （ 1.0 ± 0.7 ） mmol/L ; control group ： （ 1.2 - 0.7 ） mmol/L vs （ 0.9 ± 0.9 ） mmol/L ] , and there were significant differences （ P 〈 0.01 or P 〈 0.05 ）. After treatment, the levels of γ-GT, AST, TC, TG in treatment were lower than those in control group, and the level of HDL-C was higher than that in control group （ P 〈 0.05 ）. Conclusion The Jiangzhi hugan capsules have good liver protection and lipid-lowering effects.

关 键 词：降脂护肝胶囊 脂肪肝 疗效 临床观察 

分 类 号：R575[医药卫生—消化系统]